PharmaCyte Biotech effects 1-for-1,500 reverse stock split, reduces outstanding shares to ~1.6M

PharmaCyte Biotech, Inc.

Reverse stock split ratio 1:1,500; outstanding shares reduced from ~2.4B to ~1.6M.
Authorized shares decreased from 50B to 33,333,334; par value unchanged at $0.0001.
Effective July 12, 2021; temporary ticker PMCBD for 20 business days, then revert to PMCB.
CEO states split is a necessary step before Nasdaq listing and to support financing.
No fractional shares issued; proportionate voting power unaffected; rounding up to whole share.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.